Osteonecrosis of the jaw associated with the use of bisphosphonates and denosumab: how to prevent, when to suspect, how to diagnose and what to do.
In partnership with:
Presenter: Ourania Nicolatou-Galitis, Professor & Head Clinic of Hospital Dentistry & Dental Oncology Unit, Dental School, University of Athens, Athens, Greece; President of international Society of Oral Oncology-ISOO, Chair of Bone study Group of Multinational Association of Supportive Care in Cancer – MASCC
Osteonecrosis of the jaw (ONJ) associated with the use of bisphosphonates and denosumab is a rare complication, which may be observed primarily in patients with cancer and bone metastases who receive these medications. Increased duration of treatment and dose increase the risk of ONJ.
A multi-disciplinary approach to ONJ involving physicians, nurses, dentists and the patient is crucial. Dentists can play a key role in the prevention, prompt diagnosis and effective management of ONJ. Educational initiatives are ongoing across the European Union to increase awareness of ONJ; guidelines and best practice for dentists are under construction.